Can Avastin’s Shortcomings Open the Door for Del Mar Pharmaceuticals?
June 14 2013
The effectiveness of Genentech and Roche’s (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin’s approval for treating GBM.


Bioinformatics Part II: Application, Manipulation, and Uses
June 6 2013
Or, How I Learned to Stop Worrying and Love Computational Biology.


Okairos: Okay After All
June 5 2013
On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines.


NanoViricides: Big Things In a Small Package
June 4 2013
During an interview with OneMedPlace, President and Chairman of NanoViricides (NNVC) Anil Diwan summed up the influenza treatment market in just a few words: It is like trying to hit a moving target.